Forsinkede kurser. Sist oppdatert: onsdag 24. april  

24/01-2019 16:34:00: (NANO) Nordic Nanovector ASA (OSE: NANO) nomination committee proposes new Chairman

Oslo, Norway, 24 January 2019

In the nomination committee's recommendation to the Company's annual general
meeting in 2018, it was informed that the chairman of the board, Ludvik Sandnes,
wanted to withdraw from his position and that the nomination committee would
start work on finding a new chairman of the board.

The nomination committee has identified an experienced and well-suited candidate
and proposes that an extraordinary general meeting ("EGM") should be held to
elect Dr. Jan H. Egberts as a new board member and chairman of the board. The
Company will summon an EGM for this purpose in due course.

Jan H. Egberts, M.D. has over 25 years of experience in the pharmaceutical and
medical devices sector. He gained his medical qualifications from Erasmus
University Medical School in the Netherlands and pursued the final year of his
medical education at Harvard Medical School in the USA. Dr. Egberts also
obtained an MBA from Stanford University in the USA. After Stanford, he joined
McKinsey & Co. as a strategic consultant in New York, after which he held
various business development and general management positions of increasing
responsibility in the USA at Merck & Co. and Johnson & Johnson. Dr Egberts was
also the CEO of Octoplus a publicly listed company acquired by Dr. Reddy's

Dr. Egberts is currently the Managing Partner of Veritas Investments, a family
investment firm focused on investments in healthcare companies in the US and
Europe. Dr. Egberts also serves as the Chairman of Photocure ASA (Oslo, PHO) and
on the board of Pharming (AEX; PHARM). He is on the board of a number of
privately held companies and foundations. During his career, Dr. Egberts has
held over 20 Supervisory Board positions both in the US and various European

For further information, please contact:

Eduardo Bravo, CEO

Cell: +34 609 481 091


Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762


International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571


About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Norwegian Securities Trading Ac

Ekstern link:

Nyheten er levert av OBI.